All entries for: Biogen

November 8, 2023

Biogen

Negative Outlook

Cambridge, MA
5,001-10,000 employees
5001-10000 employees

“The IRA’s drug pricing controls and Medicare redesign may have an adverse impact on our sales (particularly for our products that are more substantially reliant on Medicare reimbursement), our business and our results of operations. However, the degree of impact from this legislation on our business depends on a number of implementation decisions. We will continue to assess as further information becomes available.”

Disease Area: Neurological Diseases
Drug Type: Biologic, Small Molecule
July 25, 2023

Biogen

Negative Outlook

Cambridge, MA
5,001-10,000 employees
5001-10000 employees
Disease Area: Neurological Diseases
Drug Type: Biologic, Small Molecule
April 25, 2023

Biogen

Negative Outlook

Cambridge, MA
5,001-10,000 employees
5001-10000 employees
Disease Area: Neurological Diseases
Drug Type: Biologic, Small Molecule
October 25, 2022

Biogen

Negative Outlook

Cambridge, MA
5,001-10,000 employees
5001-10000 employees

IRA is Notable Example of Pricing Pressure: “Drug prices are under significant scrutiny in the markets in which our products are prescribed, for example the Inflation Reduction Act of 2022 (the IRA) has certain provisions related to drug pricing. We expect drug pricing and other health care costs to continue to be subject to intense political and societal pressures on a global basis” • Uncertainty: “The overall impact that the IRA will have on our business, results of operations and financial condition, and the impact on the pharmaceutical industry as a whole is not yet known. We will continue to assess as further information becomes available”

Disease Area: Neurological Diseases
Drug Type: Biologic, Small Molecule
October 25, 2022

Biogen

Negative Outlook

Cambridge, MA
5,001-10,000 employees
5001-10000 employees
Drug Type: Biologic, Small Molecule
Scroll to Top